(Q33380002)

English

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

M Dank

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Zaluski

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C Barone

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

V Valvere

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Yalcin

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C Peschel

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Wenczl

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E Goker

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L Cisar

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K Wang

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

R Bugat

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

16 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1450-1457

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Incidence and mortality from stomach cancer in Japan, Slovenia and the USA.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Patterns of initial recurrence in completely resected gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Design and analysis of non-inferiority mortality trials in oncology.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Capecitabine as adjuvant treatment for stage III colon cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN166

21 January 2018

Identifiers

10.1093/ANNONC/MDN166

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

release_t445mekmhjh77dpct63ty6r2sm

1 reference

https://api.fatcat.wiki/v0/release/t445mekmhjh77dpct63ty6r2sm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33380002&oldid=1837259021"